Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells

Authors: Manish Tandon, Karthiga Gokul, Syed A Ali, Zujian Chen, Jane Lian, Gary S Stein, Jitesh Pratap

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

The Runt-related transcription factor Runx2 is essential for bone development but is also implicated in progression of several cancers of breast, prostate and bone, where it activates cancer-related genes and promotes invasive properties. The transforming growth factor β (TGF-β) family member bone morphogenetic protein-3B (BMP-3B/GDF10) is regarded as a tumor growth inhibitor and a gene silenced in lung cancers; however the regulatory mechanisms leading to its silencing have not been identified.

Results

Here we show that Runx2 is highly expressed in lung cancer cells and downregulates BMP-3B. This inverse relationship between Runx2 and BMP-3B expression is further supported by increased expression of BMP-3B in mesenchymal cells from Runx2 deficient mice. The ectopic expression of Runx2, but not DNA binding mutant Runx2, in normal lung fibroblast cells and lung cancer cells resulted in suppression of BMP-3B levels. The chromatin immunoprecipitation studies identified that the mechanism of Runx2-mediated suppression of BMP-3B is due to the recruitment of Runx2 and histone H3K9-specific methyltransferase Suv39h1 to BMP-3B proximal promoter and a concomitant increase in histone methylation (H3K9) status. The knockdown of Runx2 in H1299 cells resulted in decreased histone H3K9 methylation on BMP-3B promoter and increased BMP-3B expression levels. Furthermore, co-immunoprecipitation studies showed a direct interaction of Runx2 and Suv39h1 proteins. Phenotypically, Runx2 overexpression in H1299 cells increased wound healing response to TGFβ treatment.

Conclusions

Our studies identified BMP-3B as a new Runx2 target gene and revealed a novel function of Runx2 in silencing of BMP-3B in lung cancers. Our results suggest that Runx2 is a potential therapeutic target to block tumor suppressor gene silencing in lung cancer cells.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60: 277-300. 10.3322/caac.20073CrossRefPubMed
2.
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nature Rev Genet. 2002, 3: 415-428.CrossRefPubMed
3.
4.
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997, 89: 755-764. 10.1016/S0092-8674(00)80258-5CrossRefPubMed
5.
Choi J-Y, Pratap J, Javed A, Zaidi SK, Xing L, Balint E, Dalamangas S, Boyce B, van Wijnen AJ, Lian JB, Stein JL, Jones SN, Stein GS: Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA. 2001, 98: 8650-8655. 10.1073/pnas.151236498PubMedCentralCrossRefPubMed
6.
Blyth K, Cameron ER, Neil JC: The runx genes: gain or loss of function in cancer. Nat Rev Cancer. 2005, 5: 376-387. 10.1038/nrc1607CrossRefPubMed
7.
Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C, Soong R, Pho RW, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ: Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep. 2009, 36: 153-158. 10.1007/s11033-008-9378-1PubMedCentralCrossRefPubMed
8.
Pratap J, Lian JB, Stein GS: Metastatic bone disease: role of transcription factors and future targets. Bone. 2011, 48: 30-36. 10.1016/j.bone.2010.05.035PubMedCentralCrossRefPubMed
9.
Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB: Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2010, 29: 811-821. 10.1038/onc.2009.389PubMedCentralCrossRefPubMed
10.
Selvamurugan N, Partridge NC: Constitutive expression and regulation of collagenase-3 in human breast cancer cells. Mol Cell Biol Res Commun. 2000, 3: 218-223. 10.1006/mcbr.2000.0215CrossRefPubMed
11.
Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER: Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res. 2006, 66: 2195-2201. 10.1158/0008-5472.CAN-05-3558CrossRefPubMed
12.
Stewart M, Mackay N, Hanlon L, Blyth K, Scobie L, Cameron E, Neil JC: Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res. 2007, 67: 5126-5133. 10.1158/0008-5472.CAN-07-0433PubMedCentralCrossRefPubMed
13.
Bae SC, Lee KS, Zhang YW, Ito Y: Intimate relationship between TGF-beta/BMP signaling and runt domain transcription factor, PEBP2/CBF. J Bone Joint Surg Am. 2001, 83-A (Suppl 1(Pt 1): S48-S55.PubMed
14.
Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, Adams SL: Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am. 2001, 83-A (Suppl 1(Pt 1)): S15-S22.PubMed
15.
Takao M, Hino J, Takeshita N, Konno Y, Nishizawa T, Matsuo H, Kangawa K: Identification of rat bone morphogenetic protein-3b (BMP-3b), a new member of BMP-3. Biochem Biophys Res Commun. 1996, 219: 656-662. 10.1006/bbrc.1996.0289CrossRefPubMed
16.
Hino J, Takao M, Takeshita N, Konno Y, Nishizawa T, Matsuo H, Kangawa K: cDNA cloning and genomic structure of human bone morphogenetic protein-3B (BMP-3b). Biochem Biophys Res Commun. 1996, 223: 304-310. 10.1006/bbrc.1996.0889CrossRefPubMed
17.
Zhao R, Lawler AM, Lee SJ: Characterization of GDF-10 expression patterns and null mice. Dev Biol. 1999, 212: 68-79. 10.1006/dbio.1999.9326CrossRefPubMed
18.
Hino J, Matsuo H, Kangawa K: Bone morphogenetic protein-3b (BMP-3b) gene expression is correlated with differentiation in rat calvarial osteoblasts. Biochem Biophys Res Commun. 1999, 256: 419-424. 10.1006/bbrc.1999.0341CrossRefPubMed
19.
Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA: Novel regulators of bone formation: molecular clones and activities. Science. 1988, 242: 1528-1534. 10.1126/science.3201241CrossRefPubMed
20.
Kaihara S, Bessho K, Okubo Y, Sonobe J, Komatsu Y, Miura M, Miyatake S, Nakao K, Iizuka T: Over expression of bone morphogenetic protein-3b (BMP-3b) using an adenoviral vector promote the osteoblastic differentiation in C2C12 cells and augment the bone formation induced by bone morphogenetic protein-2 (BMP-2) in rats. Life Sci. 2003, 72: 1683-1693. 10.1016/S0024-3205(02)02477-3CrossRefPubMed
21.
Dai Z, Lakshmanan RR, Zhu WG, Smiraglia DJ, Rush LJ, Frühwald MC, Brena RM, Li B, Wright FA, Ross P, Otterson GA, Plass C: Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia. 2001, 3: 314-323. 10.1038/sj.neo.7900162PubMedCentralCrossRefPubMed
22.
Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A, Tannehill-Gregg S, Morrison CD, Auer H, Kratzke RA, Niehans G, Amatschek S, Sommergruber W, Leone GW, Rosol T, Otterson GA, Plass C: Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene. 2004, 23: 3521-3529. 10.1038/sj.onc.1207441CrossRefPubMed
23.
Kraunz KS, Nelson HH, Liu M, Wiencke JK, Kelsey KT: Interaction between the bone morphogenetic proteins and Ras/ MAP-kinase signalling pathways in lung cancer. Br J Cancer. 2005, 93: 949-952. 10.1038/sj.bjc.6602790PubMedCentralCrossRefPubMed
24.
Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB: The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol. 2005, 25: 8581-8591. 10.1128/MCB.25.19.8581-8591.2005PubMedCentralCrossRefPubMed
25.
Kimura K, Toyooka S, Tsukuda K, Yamamoto H, Suehisa H, Soh J, Otani H, Kubo T, Aoe K, Fujimoto N, Kishimoto T, Sano Y, Pass HI, Date H: The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. Oncol Rep. 2008, 20: 1265-1268.PubMed
26.
Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, Kouzarides T: Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 2001, 410: 120-124. 10.1038/35065138CrossRefPubMed
27.
Nakayama J, Rice JC, Strahl BD, Allis CD, Grewal SI: Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science. 2001, 292: 110-113. 10.1126/science.1060118CrossRefPubMed
28.
Choi KY, Kim HJ, Lee MH, Kwon TG, Nah HD, Furuichi T, Komori T, Nam SH, Kim YJ, Kim HJ, Ryoo HM: Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn. 2005, 233: 115-121. 10.1002/dvdy.20323CrossRefPubMed
29.
Dickmeis T, Rastegar S, Aanstad P, Clark M, Fischer N, Korzh V, Strähle U: Expression of the anti-dorsalizing morphogenetic protein gene in the zebrafish embryo. Dev Genes Evol. 2001, 211: 568-572. 10.1007/s00427-001-0190-3CrossRefPubMed
30.
Franceschi RT, Xiao G: Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem. 2003, 88: 446-454. 10.1002/jcb.10369CrossRefPubMed
31.
Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS: Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA. 2005, 102: 1454-1459. 10.1073/pnas.0409121102PubMedCentralCrossRefPubMed
32.
Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS: Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 2006, 25: 589-600.CrossRefPubMed
33.
Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY, Kuo PL: Lung tumor associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway. J Biol Chem. 2011, 286: 37335-37346. 10.1074/jbc.M111.256156PubMedCentralCrossRefPubMed
34.
Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB: Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 2008, 68: 7795-7802. 10.1158/0008-5472.CAN-08-1078PubMedCentralCrossRefPubMed
35.
Brubaker KD, Vessella RL, Brown LG, Corey E: Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate. 2003, 56: 13-22. 10.1002/pros.10233CrossRefPubMed
36.
Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S: RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006, 66: 6512-6520. 10.1158/0008-5472.CAN-06-0369CrossRefPubMed
37.
Inman CK, Shore P: The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem. 2003, 278: 48684-48689. 10.1074/jbc.M308001200CrossRefPubMed
38.
Leong DT, Lim J, Goh X, Pratap J, Pereira BP, Kwok HS, Nathan SS, Dobson JR, Lian JB, Ito Y, Voorhoeve PM, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ: Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res. 2010, 12: R89- 10.1186/bcr2762PubMedCentralCrossRefPubMed
39.
Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B: Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer. 2010, 9: 258-275. 10.1186/1476-4598-9-258PubMedCentralCrossRefPubMed
40.
Upadhyay G, Yin Y, Yuan H, Li X, Derynck R, Glazer RI: Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-{beta} signaling. Proc Natl Acad Sci USA. 2011, 108: 7820-7825. 10.1073/pnas.1103441108PubMedCentralCrossRefPubMed
41.
Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR: Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell. 2002, 111: 621-633. 10.1016/S0092-8674(02)01111-XCrossRefPubMed
42.
Chakraborty S, Sinha KK, Senyuk V, Nucifora G: SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo. Oncogene. 2003, 22: 5229-5237. 10.1038/sj.onc.1206600CrossRefPubMed
43.
Lian JB, Stein JL, Stein GS, van Wijnen AJ, Montecino M, Javed A, Gutierrez S, Shen J, Zaidi SK, Drissi H: Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res. 2003, 44 (Suppl 1): 141-148.CrossRefPubMed
44.
Boumah CE, Lee M, Selvamurugan N, Shimizu E, Partridge NC: Runx2 recruits p300 to mediate parathyroid hormone's effects on histone acetylation and transcriptional activation of the matrix metalloproteinase-13 gene. Mol Endocrinol. 2009, 8: 1255-1263.CrossRef
45.
Young DW, Hassan MQ, Pratap J, Galindo M, Zaidi SK, Lee SH, Yang X, Xie R, Javed A, Underwood JM, Furcinitti P, Imbalzano AN, Penman S, Nickerson JA, Montecino MA, Lian JB, Stein JL, van Wijnen AJ, Stein GS: Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature. 2007, 445: 442-446. 10.1038/nature05473CrossRefPubMed
46.
Ali SA, Zaidi SK, Dacwag CS, Salma N, Young DW, Shakoori AR: Phenotypic transcription factors epigenetically mediate cell growth control. Proc Natl Acad Sci USA. 2008, 105: 6632-6637. 10.1073/pnas.0800970105PubMedCentralCrossRefPubMed
47.
Westendorf JJ: Transcriptional co-repressors of Runx2. J Cell Biochem. 2006, 98: 54-64. 10.1002/jcb.20805CrossRefPubMed
48.
Lamour V, Detry C, Sanchez C, Henrotin Y, Castronovo V, Bellahcène A: Runx2-and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem. 2007, 282: 36240-36249. 10.1074/jbc.M705833200CrossRefPubMed
49.
McGee-Lawrence ME, Bradley EW, Westendorf JJ: Hdac-mediated control of endochondral and intramembranous ossification. Crit Rev Eukaryot Gene Expr. 2011, 21: 101-113.PubMedCentralCrossRefPubMed
Metadata
Title
Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells
Authors
Manish Tandon
Karthiga Gokul
Syed A Ali
Zujian Chen
Jane Lian
Gary S Stein
Jitesh Pratap
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-27

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Research

Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck

Research

Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis

Research

Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice

Erratum

Erratum to: Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer

Research

Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma

Research

Highly efficient site-specific transgenesis in cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits